SCHEMBL6921653

SCHEMBL6921653

Cc1cc(C(=O)CN(C)c2ccccc2)c(C)n1-c1ccc(F)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 4/20 0.60
KDM4E B2RXH2 3/20 0.56
USP14 P54578 2/20 0.56
USP7 Q93009 1/20 0.56
RAB9A P51151 9/20 0.55
SMN1; SMN2 Q16637 8/20 0.55
NPC1 O15118 8/20 0.55
HPGD P15428 3/20 0.55
USP5 P45974 1/20 0.55
LMNA P02545 4/20 0.53
HTT P42858 2/20 0.51
TP53 P04637 1/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
ALDH1A1 P00352 3/20 0.50
RXFP1 Q9HBX9 1/20 0.47
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6921657 0.85 NOTUM (0.65) NOTUMKDM4EUSP14USP7RAB9A
SCHEMBL2552359 0.82 RAB9A (0.60) NOTUMKDM4EUSP14USP7RAB9A
SCHEMBL6923175 0.81 SMN1; SMN2 (0.64) NOTUMKDM4EUSP14USP7RAB9A
SCHEMBL6922827 0.81 NOTUM (0.59) NOTUMKDM4EUSP14USP7RAB9A
SCHEMBL6923099 0.80 SMN1; SMN2 (0.65) NOTUMKDM4EUSP14USP7RAB9A
SCHEMBL6923288 0.79 NOTUM (0.56) NOTUMKDM4EUSP14USP7RAB9A
SCHEMBL6921809 0.77 NOTUM (0.61) NOTUMKDM4EUSP14USP7RAB9A
SCHEMBL18452326 0.77 ALDH1A1 (0.71) NOTUMKDM4EUSP14USP7RAB9A
SCHEMBL1979515 0.76 NOTUM (1.00) NOTUMKDM4EUSP14USP7RAB9A
SCHEMBL6922311 0.75 NOTUM (0.65) NOTUMKDM4EUSP14USP7RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351568-B2 Compositions and methods for enhancing proteasome activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-07-16 US disclosed
US-9849135-B2 USP14 inhibitors for treating or preventing viral infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-26 US disclosed
US-9849135-B2 USP14 inhibitors for treating or preventing viral infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-26 US disclosed
EP-2528911-B1 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY HARVARD COLLEGE (US) 2017-10-25 EP disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 US disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 US disclosed
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-11-26 US disclosed
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-11-26 US disclosed
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 US disclosed
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 US disclosed
WO-2014116228-A1 USP14 INHIBITORS FOR TREATING OR PREVENTING VIRAL INFECTIONS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-07-31 WO disclosed
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-21 US disclosed
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-21 US disclosed
WO-2011094545-A2 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections USP14, USP1, USP13 NOTUM 2093/4885KDM4E 1417/4885USP14 1/4885
US-10351568-B2 Compositions and methods for enhancing proteasome activity PSMG3, PSME3, PSMB11 NOTUM 2331/4885KDM4E 2300/4885USP14 12/4885
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSMB11, PSME3 NOTUM 2305/4885KDM4E 2238/4885USP14 6/4885
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSME3, PSMB11 NOTUM 2331/4885KDM4E 2300/4885USP14 12/4885
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation HSPA2, HSPBP1, HSPH1 NOTUM 3253/4885KDM4E 943/4885USP14 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.